Verona Pharma PLC ADR Total Liabilities
Verona Pharma PLC ADR total liabilities. Based on the latest financial reports, Verona Pharma PLC ADR (VRNA) has total liabilities worth $294.60 Million USD as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Verona Pharma PLC ADR (VRNA) defensive interval to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Verona Pharma PLC ADR (2005–2024)
Total liabilities of Verona Pharma PLC ADR from 2005 to 2024. This chart illustrates how Verona Pharma PLC ADR's total liabilities have evolved over time, based on quarterly financial data. Check how resilient are Verona Pharma PLC ADR's assets to evaluate the company's liquid asset resilience ratio.
Verona Pharma PLC ADR Competitors by Total Liabilities
The table below lists competitors of Verona Pharma PLC ADR ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
UGI Corporation
NYSE:UGI
|
USA | $10.41 Billion |
|
Tingyi (Cayman Islands) Holding Corp
F:TYG
|
Germany | €36.44 Billion |
|
Silicon Motion Technology Corporation
F:S9M
|
Germany | €400.89 Million |
|
Andritz AG
VI:ANDR
|
Austria | €5.59 Billion |
|
BARRY CALLEBA. ADR 1/100
F:BCLM
|
Germany | €9.49 Billion |
|
Clearwater Analytics Holdings Inc
NYSE:CWAN
|
USA | $972.29 Million |
|
Gigabyte Technology Co Ltd
TW:2376
|
Taiwan | NT$180.78 Billion |
|
Engie Brasil Energia S.A.
SA:EGIE3
|
Brazil | R$42.91 Billion |
Liability Composition Analysis (2005–2024)
This chart breaks down Verona Pharma PLC ADR's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Verona Pharma PLC ADR total assets.
Liquidity & Leverage Metrics
Verona Pharma PLC ADR Total Liabilities Ratios Explained
Verona Pharma PLC ADR total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 10.71 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.51 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Verona Pharma PLC ADR's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Verona Pharma PLC ADR (2005–2024)
The table below shows the annual total liabilities of Verona Pharma PLC ADR from 2005 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $269.68 Million | +358.32% |
| 2023-12-31 | $58.84 Million | +102.89% |
| 2022-12-31 | $29.00 Million | -24.83% |
| 2021-12-31 | $38.58 Million | +99.37% |
| 2020-12-31 | $19.35 Million | +30.96% |
| 2019-12-31 | $14.78 Million | +2.81% |
| 2018-12-31 | $14.37 Million | +10.52% |
| 2017-12-31 | $13.00 Million | -9.71% |
| 2016-12-31 | $14.40 Million | +436.34% |
| 2015-12-31 | $2.69 Million | +229.08% |
| 2014-12-31 | $816.08K | +1.14% |
| 2013-12-31 | $806.89K | +150.50% |
| 2012-12-31 | $322.11K | +32.99% |
| 2011-12-31 | $242.21K | -23.82% |
| 2010-12-31 | $317.94K | -31.49% |
| 2009-12-31 | $464.08K | +277.27% |
| 2008-12-31 | $123.01K | -60.49% |
| 2007-12-31 | $311.35K | +140.79% |
| 2006-12-31 | $129.31K | +526.24% |
| 2005-12-31 | $20.65K | -- |
About Verona Pharma PLC ADR
Verona Pharma plc, a biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company offers Ohtuvayre, a dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that combines bronchodilator and non-steroidal anti-inflammatory effects for the maintenance treatment of chronic obstructive pu… Read more